A Multicenter, Open-Label Study of the Safety and Tolerability of Transitioning From Remodulin to Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension

Trial Profile

A Multicenter, Open-Label Study of the Safety and Tolerability of Transitioning From Remodulin to Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jun 2016

At a glance

  • Drugs Treprostinil (Primary) ; Treprostinil (Primary) ; Treprostinil (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions
  • Sponsors United Therapeutics Corporation
  • Most Recent Events

    • 23 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 09 Aug 2014 New trial record
    • 01 Jul 2014 Status changed from recruiting to active, no longer recruiting according to results published in the Journal of Heart and Lung Transplantation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top